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Introduction: Macrolides are of unique interest in preventing COPD exacerbations because
they possess a variety of antibacterial, antiviral and anti-inflammatory properties. Recent
research has generated renewed interest in prophylactic macrolides to reduce the risk of COPD
exacerbations. Little is known about how well these recent findings fit within the context of
previous research on this subject. The purpose of this article is to evaluate, via exploratory
meta-analysis, whether the overall consensus favors prophylactic macrolides for prevention
of COPD exacerbations.
Methods: EMBASE, Cochrane and Medline databases were searched for all relevant randomized
controlled trials (RCTs). Six RCTs were identified. The primary endpoint was incidence of COPD
exacerbations. Secondary endpoints including mortality, hospitalization rates, adverse events
and likelihood of having at least one COPD exacerbation were also examined.
Results: There was a 37% relative risk reduction (RR Z 0.63, 95% CI: 0.45e0.87, p
valueZ 0.005) in COPD exacerbations among patients taking macrolides compared to placebo.tive Pulmonary Disease; RCT, randomized controlled trial; ITT, Intention-to-Treat.
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1386 E. Donath et al.Furthermore, there was a 21% reduced risk of hospitalization (RRZ 0.79, 95% CI: 0.69e0.90, p-
valueZ 0.01) and 68% reduced risk of having at least one COPD exacerbation (RRZ 0.34, 95%
CI 0.21e0.54, p-value Z 0.001) among patients taking macrolides versus placebo. There was
also a trend toward decreased mortality and increased adverse events among patients taking
macrolides but these were not statistically significant.
Conclusions: Prophylactic macrolides are an effective approach for reducing incident COPD ex-
acerbations. There were several limitations to this study including a lack of consistent adverse
event reporting and some degree of clinical and statistical heterogeneity between studies.
Published by Elsevier Ltd.Introduction
Individuals with Chronic Obstructive Pulmonary Disease
(COPD) who suffer recurrent disease exacerbations are
likely to see rapid declines in quality of life, lung function
and lifespan.1 As a result, there is a strong interest in
developing approaches that can mitigate this substantial
problem. While the spectrum of available COPD treatments
provide some benefit, they are insufficient. Additional ap-
proaches are sorely needed.
As far back as the 1960s, there has been interest in
employing prophylactic antibiotics to reduce the incidenceof
COPDexacerbations.Most of these trials arewell summarized
in a 2003 Cochrane meta-analysis that concluded the risk
reduction (of recurrent exacerbations) with antibiotics was
approximately 9%.2 However, there was a wide degree of
heterogeneity in reporting methods and trial design, as well
as significant antibiotic-related side effects and drug resis-
tance. So while antibiotics were beneficial in reducing inci-
dence of COPD exacerbations, its associated risks rendered it
an ultimately unappealing option. More recently, reports
emerged that macrolides, given on a long-term basis, had a
beneficial effect in reducing disease progression of diffuse
panbronchiolitis3 and cystic fibrosis.4 This prompted renewed
interest in using specifically macrolides for prevention of
COPD exacerbations. Macrolides are of unique interest
because, in addition to their antibacterial effects, they
possess antiviral and immunomodulatory activity e and all
three of these properties seemingly work in concert to pre-
vent and/or treat disease exacerbations.5 As a result, over
the past two decades, several small-scale, well-designed and
well-executed trials have been launched, highlighted by the
recent study by Albert et al.,6 which seems to have generated
newfound interest in the notion of using prophylactic mac-
rolides to reduce the risk of COPDexacerbations. Thepurpose
of this study is to evaluate via a meta-analysis whether the
overall bodyof research supports thenotion thatprophylactic
macrolides are effective in preventing COPD exacerbations.
Furthermore, whether results from the five randomized
controlled trials (RCTs) that preceded the Albert et al.6 study
were consistentwith each other and in linewith findings from
that particular groundbreaking study.
Materials and methods
Search strategy
A comprehensive search of MEDLINE, Cochrane Central
Register of Controlled Trials and EMBASE was performed.There was no time limit on the search. There were no
specific restrictions regarding study length. All English,
Spanish and French articles were included. Databases were
fully explored for all potential RCTs by conducting a highly
sensitive search strategy using the MESH keywords: Chronic
Obstructive Pulmonary Disease AND Macrolides or Erythro-
mycin or Clarithromycin or Azithromycin AND randomized
controlled trials or controlled clinical trials. A secondary
“hand-search” was then pursued e this consisted of indi-
vidually scanning all abstracts from the 2010, 2011 and 2012
American Thoracic Society Annual Conference, European
Respiratory Society Congress as well as the CHEST Annual
Conference to identify studies that had not yet been pub-
lished or accessible on the aforementioned medical data-
bases. Additionally, all selected articles were reviewed for
other relevant articles.
Study selection
The initial search strategy yielded 341 studies. Drs
Chaudhry and Donath evaluated each study for inclusion in
the meta-analysis separately. Dr Hernandez mediated dis-
agreements regarding any specific study. Of these 341
studies, six studies were ultimately selected for inclusion in
the meta-analysis (Fig. 1). An additional two cohort studies
were also noted, but not included as part of the overall
meta-analysis.
Assessment of validity
The methodological quality of all included trials was
assessed according to randomization method, concealment
of random allocation, eligibility criteria, comparability of
baseline characteristics, blinding of outcome assessors,
blinding of treatment providers, blinding of patients and
whether the trial employed Intention-to-Treat (ITT)
Analysis.
Data extraction and synthesis
Data was abstracted from all studies using standardized
forms. Of studies selected, a variety of specific trials
characteristics were recorded including study design,
macrolide dosing/duration, age, sex, smoking history and
COPD severity. These trial characteristics were considered
the key variables that may have influenced effect size and
were explored further via meta regression and subgroup
analyses. The primary endpoint was the total number of
COPD exacerbations as a function of person-years. A COPD
Figure 1 Flow diagram depicting number of studies included
at each stage of selection process.
A meta-analysis on the prophylactic use of macrolide antibiotics 1387exacerbation was defined as a sudden worsening in respi-
ratory symptoms typically lasting multiple days and char-
acterized by at least two of three symptoms: dyspnea,
increased quantity of sputum and purulent sputum. Sec-
ondary endpoints included mortality, hospitalization rates,
adverse events leading to study withdrawal and likelihood
of having at least one COPD exacerbations. Results,
extracted specifically from intention-to-treat (ITT) data,
were expressed as a relative risk (RR) with accompanying
95% confidence intervals. If RR values weren’t explicitly
provided by authors, they were calculated using provided
study data. Meta-analyses were then pursued using
random-effects modeling for the primary endpoint and
fixed-effects modeling for the secondary endpoints. The I2
statistic and forest plots were used to assess the degree of
heterogeneity. Causes of heterogeneity were subsequently
explored via subgroup analyses and meta regression.
Sensitivity analyses were used to assess the impact of
excluding studies based on methodological quality. The
analysis was performed using Stata 11 (Stata Statistical
Software, College Station, TX).
Results
Six studies were identified for inclusion into the meta-ana-
lysis.6e11 These studieswere all conductedwithin the past 10years. They generally included patients among the ages of
65e75. They were mostly evaluating patients with severe to
very severe COPD with baseline FEV1% values ranging from
20% to 50%. Most patients included in these studies had a
history of recurrent COPD exacerbations although only
Albert et al.6 specifically required patients to have had at
least one COPD exacerbation in the year prior to study entry
(they could also be included if they were using supplemental
oxygen at-home without necessarily having had an exacer-
bation in the prior year). Studies lasted for 3e12 months
(Table 1). Two of the six RCTs were not blinded; there were
otherwise no major study biases that were consistently
identified among included studies (Table 2).
The primary endpoint was the total number of exacer-
bations as a function of person-years. The comprehensive
meta-analysis, involving six studies and 1677 patients,
showed that there was 37.3% relative risk reduction
(RR Z 0.627, 95% CI: 0.452e0.868, p value Z 0.005, I-
squared 62.8%) in exacerbations among patients taking
macrolides compared to those taking a placebo (Fig. 2). An
additional two cohort studies, not suitable for inclusion into
themetaanalysis,were identified that further supported this
conclusion.15,16 As the recent Albert et al. study6 accounted
for a large percentage of the overall effect, a sensitivity
analysis was conducted involving the five other RCTs. That
meta-analysis, involving 333 patients, found a 48.1% relative
risk reduction of exacerbations among patients taking mac-
rolides compared to those taking a placebo (RRZ 0.519, 95%
CI: 0.315e0.855, p valueZ 0.01, I-squared 49%).
Additional secondary endpoints were also explored. In
terms of mortality risk, three studies addressing that
outcome6,9,11 found a 15% risk reduction in overall mortality
among patients taking prophylactic macrolides compared
to those taking placebo (RR Z 0.85, 95% CI: 0.49e1.46, p-
value Z 0.55, I-squared 0%) (Fig. 3). In terms of hospitali-
zation risk, three studies addressing that outcome6,8,9
found a 21% risk reduction in overall number of hospitali-
zations among patients taking prophylactic macrolides
compared to those taking placebo (RR Z 0.79, 95% CI:
0.69e0.90, p-valueZ 0.01, I-squared 0%) (Fig. 4). In terms
of likelihood of having at least one COPD exacerbation, two
studies addressing that outcome9,10 found a 68% risk
reduction (RR Z 0.34, 95% CI 0.21e0.54, p-value Z 0.001,
I-squared 87%) in having at least one COPD exacerbation
among patients taking prophylactic macrolides compared
to those taking placebo (Fig. 5). Lastly, in terms of relative
risk of having some adverse event leading to study with-
drawal, all six studies6e11 addressing that outcome found a
95% increased risk of withdrawal due to adverse event
among patients taking prophylactic macrolides compared
to those taking placebo (RR Z 1.95, 95% CI 0.92e4.14, p-
value Z 0.08, I-squared 0%) (Fig. 6).
Several additional study variables including average age,
COPD severity and pack-years of smoking were prospec-
tively explored further via subgroup analyses and meta-
regression. Through meta-regression, there was a highly
statistically significant negative correlation between the
mean number of pack-years patients smoked and response
to macrolides (i.e. patients with more pack-years of
smoking were less likely to respond to macrolides). The
adjusted R-squared for this relationship was 96% (p-
value Z 0.04, I2 Z 0%).
Table 1 Major study characteristics from the six RCTs included in the meta-analysis.
Banerjee D,
Khair OA et al.
Albert R,
Connett J
et al.
Blasi F,
Bonardi D
et al.
Seemungal T,
Wilkinson T et al.
Suzuki T,
Yanai M et al.
He Z, Ou L
et al.
Study design RCT RCT RCT RCT RCT RCT
Year of study 2003e2004 2006e2010 2004e2006 2004e2006 1997e1999 2008e2009
Country United Kingdom United States Italy United Kingdom Japan China
Number of patients
(treatment:control)
31:36 558:559 11:11 53:56 55:54 18:18
Mean age (treatment:
control)
65:68 65:66 72:73 67:68 69.1:71.7 68.8:69.3
Pre-bronchodilator
FEV1 % predicted
(treatment:control)
42.5:43.9 39:40 e 49.3:50.6 e 44.3:42.1
Pre-bronchodilator
FEV1/FVC % predicted
(treatment:control)
e 42:43 e 48.9:50.9 e 46.9:48.6
Type of macrolide
and dose
Clarithromycin
500 mg once
daily
Azithromycin
250 mg
once daily
Azithromycin
500 mg once
3 days/week
Erythromycin
250 mg twice
daily
Erythromycin
200e400 mg
once daily
Erythromycin
125 mg 3
times daily
Inclusion in study required
one or more COPD
exacerbations in past year
No Yes No No No No
Duration of treatment 3 months 12 months 6 months 12 months 12 months 6 months
COPD severity Moderatee
severe
Moderatee
very severe
Severe Moderatee
severe
e Moderatee
severe
Exacerbations/person-year
in treatment group
0.65 1.48 0.80 1.53 0.25 1.22
Exacerbations/person-year
in control group
0.22 1.83 3.33 2.23 1.19 2.22
Relative risk (95%
confidence interval)
3.27 (95%
CI 0.53e34.33)
0.83 (95%
CI 0.72e0.95)
0.24 (95%
CI 0.05e0.83)
0.65 (95%
CI 0.49e0.86)
0.21 (95%
CI 0.07e0.65)
0.55 (95%
CI 0.31e0.98)
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COPD exacerbations are generally thought to arise as a result
of a complex interplay between bacterial and/or viral inva-
sion associated with an aberrant immune response. Bacteria
(most commonly Haemophilus influenzae, StreptococcousTable 2 Ascertainment of study bias from the six RCTs include
Randomization
method
Concealment
of random
allocation
Eligibility
criteria
Albert R,
Connett J et al.4
Yes Not
addressed
Yes
Banerjee D,
Khair OA et al.5
Yes Yes Yes
Seemungal T,
Wilkinson T et al.6
Yes Yes Yes
Blasi F, Bonardi D
et al.7
Yes No Yes
He Z, Ou L et al.8 Yes Not
addressed
Yes
Suzuki T, Yanai M
et al.9
Yes Yes Yespneumoniae and Moraxella catarrhalis) cause airway injury
and ultimately restrict airflow by increasing mucus secre-
tion, impeding mucociliary clearance and increasing smooth
muscle contraction.5 Additionally, viruses (most commonly
rhinovirus, influenza virus and respiratory syncytial virus) are
thought to cause injury to epithelial cells that impair theird in the meta-analysis.
Comparable
at baseline
Blinding of
outcome
assessors
Blinding of
treatment
providers
Blinding
of
patients
ITT
analysis
Yes Not
addressed
Not
addressed
Yes Yes
Yes Not
addressed
Not
addressed
Yes Yes
Yes Yes Yes Yes Yes
Yes No No No No
Yes Yes Yes Yes Yes
Yes No No No Not
addressed
Figure 2 Forest plot from overall meta-analysis, including all six included RCTs, assessing relative risk (RR) of COPD exacerba-
tions as a function of person-years in patients receiving macrolides compared to placebo.
A meta-analysis on the prophylactic use of macrolide antibiotics 1389barrier function and lead to epithelial detachment with
subsequent pulmonary edema, alveolar destruction and
airflow limitation.5 Lastly, COPD exacerbations seem to be
somewhat related to an underlying pro-inflammatory state
where an over-activated immune system may egregiously
respond to relatively innocuous insults.12 Macrolides serve as
a compelling treatment for prevention of COPD exacerba-
tions by addressing each of these mechanisms separately.5
These findings suggest that prophylactic macrolides
seem to have a positive net effect among individuals with
more severe forms of COPD. This benefit seemed to extend
to all outcomes that were assessed e in particular, the
incidence of COPD exacerbations, the hospitalization rateFigure 3 Forest plot assessing relative risk (RR) of death amonand likelihood of having at least one COPD exacerbation all
suggested highly statistically significant benefit favoring the
use of macrolides versus placebo. This benefit comes at the
expense of a variety of adverse events that are inconsis-
tently reported across studies. The one endpoint that was
reliably reported for all studies was the likelihood of pa-
tients discontinuing the study due to an adverse event e
and there was a trend toward high rates of study discon-
tinuation from macrolides, although this was not statisti-
cally significant. Of note, it was difficult to capture some of
the more large-scale risks associated with macrolide pro-
phylaxis including the development of macrolide resis-
tance. This is becoming an increasing concern worldwide,13g COPD patients receiving macrolides compared to placebo.
Figure 4 Forest plot assessing relative risk (RR) of hospitalization among COPD patients receiving macrolides compared to
placebo.
1390 E. Donath et al.and particularly in Asia,14 and the fact that its difficult to
characterize in the above studies does not make it any less
of a concern. It is probably the most important shortcoming
to the widespread implementation of prophylactic
macrolides.
Although the overall analysis suggested substantial
benefit from prophylactic macrolides, it worth noting that
findings from one of the six identified studies was highly
inconsistent with the rest. Banerjee D et al.7 was the one
study in which macrolides did not prevent COPD exacer-
bations. This was likely due to the limited length of the
study and the small number of total exacerbations observed
- thus limiting the power of the study to detect a trueFigure 5 Forest plot assessing relative risk (RR) of at least o
compared to placebo.effect. Of note, in addition to the five RCTs which suggest a
significant benefit for macrolides, two additional cohort
studies showed a statistically significant reduction in COPD
exacerbations among patients taking prophylactic macro-
lides. Yamaya M et al. retrospectively examined hospital
records of 131 patients and determined a relative risk
reduction of 19% (RR 0.81, 95% CI 0.69e0.95) in COPD ex-
acerbations among those patients taking prophylactic
macrolides.15 Additionally, Gomez J et al. prospectively
monitored patients being given prophylactic azithromycin
500 mg daily for three of every 21 days and found that
macrolides reduced the risk of COPD exacerbations by 45%
(RR 0.55, 95% CI 0.46e0.68).16ne COPD exacerbation among patients receiving macrolides
Figure 6 Forest plot assessing relative risk (RR) of withdrawal from study due to an adverse event among patients receiving
macrolides compared to placebo.
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findings, attempts were made to better elucidate that het-
erogeneity via meta-regression and subgroup analyses. In
particular, a meta-regression analysis was employed to
detect whether the effect size may have been related to
disease severity. There are many variables to consider in
evaluating disease severity (including %FEV1, %FVC, etc.)e
the number of pack-years smoked was examined specifically
because it was the only variable consistently reported across
studies. Interestingly, this analysis revealed that the number
of pack-years had an inverse relationship with the likelihood
of benefiting frommacrolidesewhich is the opposite ofwhat
one may have anticipated. As multiple previous studies have
established that COPD severity is directly related to one’s
smoking history17,18 this finding belies the widely held notion
that prophylactic macrolides should be reserved for in-
dividuals with only very severe COPD and suggests a possibly
expanded role for macrolides across a wider spectrum of
COPDpatients. Along these lines, in the studybyAlbert et al.6
(in which their subgroup analyses examine benefits across
patients with varying COPD severity), they demonstrate the
greatest benefit from macrolides is seen in patients with
moderate COPD (GOLD Stage 2).
There were several limitations to this analysis. Firstly,
there was some degree of clinical heterogeneity between
studies in that they originated from different countries, had
different grading criteria for COPD severity and employed
differentmacrolides under several dosing regimens. This was
the likely reason for the moderate degree of statistical het-
erogeneity (i.e. elevated I-squared values) seen across
certain endpoints. Another potential source of heterogeneity
was study length (which varied from3 to 12months). This was
partially controlled for by evaluating the primary outcome as
a function of the number of person-years under study (as
opposed to the denominator being simply the number of
persons). Additionally, adverse events were inconsistently
reported between studies andwere not fully addressed here.The potential risks associated with macrolide usage have
been under recent scrutiny in light of the finding that azi-
thromycin usage may be associated with an increased risk of
sudden cardiac death.19 Thirdly, the overall patient popula-
tion being studied in this analysis included a disproportionate
amount of patients from the recent landmark study by
Albert et al.6 As a result, a sensitivity analysis was performed
including only the five studies that preceded Albert et al.6
and, importantly, there was a statistically significant effect
favoring macrolides among those five studies alone. This
finding can serve to reinforce the conclusions made by
Albert et al.6 as well as support the overall conclusions from
this meta-analysis. Lastly, prophylactic macrolides have
become increasingly well established as an important treat-
ment consideration in non-cystic fibrosis bronchiectasis3 and
there were no screening programs in place among these
studies to identify patientswith underlying bronchiectasis. As
a result, it is difficult to tease out how many of the above
patients with COPD may have had some component of bron-
chiectasis and whether the proposed benefit from prophy-
lacticmacrolidesexists amongCOPDpatientswhodonothave
any underlying bronchiectasis.
It is important to realize that while prior meta-analyses
have evaluated the use of prophylactic antibiotics in gen-
eral for prevention of COPD exacerbations, none have
specifically addressed the use of macrolides and none have
shown a similar degree of benefit that is being suggested
here. These findings serve to bolster the current body of
evidence suggesting benefit for prophylactic macrolides
among patients with severe to very severe forms of COPD.Conflict of interest
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